Have a feature idea you'd love to see implemented?
Let us know!
EXEL Exelixis Inc
Price (delayed)
$33.29
Market cap
$9.51B
P/E Ratio
21.07
Dividend/share
N/A
EPS
$1.58
Enterprise value
$9.44B
Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work
Highlights
The P/E is 44% below the 5-year quarterly average of 37.5 and 23% below the last 4 quarters average of 27.4
The company's EPS rose by 35% QoQ
EXEL's quick ratio is down by 9% since the previous quarter but it is up by 3.1% year-on-year
The company's equity rose by 7% QoQ but it fell by 3.1% YoY
Key stats
What are the main financial stats of EXEL
Market
Valuations
Earnings
Shares outstanding
285.58M
Market cap
$9.51B
Enterprise value
$9.44B
Price to earnings (P/E)
21.07
Price to book (P/B)
4.17
Price to sales (P/S)
4.57
EV/EBIT
15.74
EV/EBITDA
14.39
EV/Sales
4.54
Revenue
$2.08B
Gross profit
$2B
Net income
$466.92M
EBIT
$599.91M
EBITDA
$656.21M
Free cash flow
$432.69M
Per share
Balance sheet
Liquidity
EPS
$1.58
EPS diluted
$1.56
Free cash flow per share
$1.51
Book value per share
$7.98
Revenue per share
$7.29
TBVPS
$10.14
Total assets
$2.96B
Total liabilities
$684.86M
Debt
$194.45M
Equity
$2.28B
Working capital
$1.16B
Debt to equity
0.09
Current ratio
3.93
Quick ratio
3.7
Net debt/EBITDA
-0.1
Margins
Efficiency
Dividend
EBITDA margin
31.5%
Gross margin
96.3%
Net margin
22.4%
Operating margin
25.1%
Return on assets
16.3%
Return on equity
21.3%
Return on invested capital
25.2%
Return on capital employed
23.4%
Return on sales
28.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EXEL stock price
How has the Exelixis stock price performed over time
Intraday
-1.16%
1 week
-4.97%
1 month
-3.92%
1 year
43.37%
YTD
38.77%
QTD
28.29%
Financial performance
How have Exelixis's revenue and profit performed over time
Revenue
$2.08B
Gross profit
$2B
Operating income
$523.2M
Net income
$466.92M
Gross margin
96.3%
Net margin
22.4%
Exelixis's operating income has increased by 42% QoQ
EXEL's operating margin is up by 37% since the previous quarter
The company's net income rose by 33% QoQ
The net margin has increased by 29% from the previous quarter
Growth
What is Exelixis's growth rate over time
Valuation
What is Exelixis stock price valuation
P/E
21.07
P/B
4.17
P/S
4.57
EV/EBIT
15.74
EV/EBITDA
14.39
EV/Sales
4.54
The P/E is 44% below the 5-year quarterly average of 37.5 and 23% below the last 4 quarters average of 27.4
The company's EPS rose by 35% QoQ
EXEL's P/B is 39% above its 5-year quarterly average of 3.0 and 26% above its last 4 quarters average of 3.3
The company's equity rose by 7% QoQ but it fell by 3.1% YoY
EXEL's price to sales (P/S) is 24% higher than its last 4 quarters average of 3.7 but 2.8% lower than its 5-year quarterly average of 4.7
The revenue has grown by 17% YoY and by 3.4% from the previous quarter
Efficiency
How efficient is Exelixis business performance
The company's return on equity rose by 35% QoQ
The ROA has grown by 34% from the previous quarter
The ROIC has grown by 31% from the previous quarter
The company's return on sales rose by 29% QoQ
Dividends
What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EXEL.
Financial health
How did Exelixis financials performed over time
EXEL's total liabilities is up by 9% year-on-year and by 4.8% since the previous quarter
EXEL's quick ratio is down by 9% since the previous quarter but it is up by 3.1% year-on-year
The debt is 91% less than the equity
The company's debt to equity rose by 13% YoY
The company's equity rose by 7% QoQ but it fell by 3.1% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.